After Cigna (CI) announced that CEO David Cordani will retire and be succeeded by current COO and former CFO Brian Evanko, Barclays contends that Evanko was “always the natural successor” and will be among the youngest CEOs in healthcare services while also one of the most tenured, calling this “a rare and attractive combination in today’s environment.” However, the timing “may surprise some investors” as Cigna enters the first year of a significant, multi-year PBM model transition, the analyst added. Noting that Cigna also reaffirmed its 2026 EPS outlook alongside the announcement, the firm keeps an Overweight rating on shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna Announces CEO Succession and Leadership Transition Plan
- Cigna says Brian Evanko to Succeed David Cordani as CEO
- Cigna backs FY26 adjusted EPS view ‘at least’ $30.25, consensus $30.32
- Cigna price target lowered to $370 from $374 at Piper Sandler
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 1